Novo Nordisk continues to benefit from the massive societal and economic waves generated by its GLP-1 therapies. As economic research highlights the profound impact of weight-loss drugs on employment and social mobility, demand for these treatments is expected to remain highly resilient. The broader implications for labor market productivity add a unique tailwind to the pharmaceutical giant's long-term market valuation.